Mammotest boosts Fischer’s 1999 results
X-ray and mammography vendor Fischer Imaging posted revenue increases for the fourth quarter and year (end-December), thanks to growth in its Mammotest stereotactic biopsy business and the restructuring of its operations last September. Mammotest sales
X-ray and mammography vendor Fischer Imaging posted revenue increases for the fourth quarter and year (end-December), thanks to growth in its Mammotest stereotactic biopsy business and the restructuring of its operations last September. Mammotest sales increased both in the U.S., through Fischers direct sales force, and in Europe, through its partnership with Johnson & Johnsons Ethicon Endo-Surgery division (SCAN 10/29/97).
The company reported fourth quarter revenues of $16.3 million, up 9% from $15 million in the same period 1998, and net income of $398,000, compared to a net loss of $4.4 million in 1998. For the year, Denver-based Fischers revenues climbed 10%, from 1998s $59.8 million to $66 million. Net loss for the year was $343,000, compared to a loss of $6.8 million in 1998.
Also during the fourth quarter, Fischer moved closer to filing a regulatory approval application with the Food and Drug Administration for its full-field digital mammography unit, SenoScan. The company has been in discussions with the FDA, according to Morgan Nields, chairman and CEO, and is in the process of evaluating whether to submit a 510(k) or a PMA.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
